Teduglutide /kg

Phase 3Peptide

Takeda

Teduglutide /kg is one of 19 small molecule programs targeting Short Bowel Syndrome. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Short Bowel SyndromeActive, not recruiting

Short Bowel SyndromePhase 3

Active, not recruiting

Competition

Competitive Landscape

28 competitors in Short Bowel Syndrome

#DrugCompanyPhaseTrials

Byetta

AstraZeneca

Approved

1 2

Eliquis

Bristol-Myers Squibb

Approved

1 3

Victoza

Growth Hormone

1 5

Ursodeoxycholic Acid

Daewoong Pharmaceutical Co. LTD.

Approved

1 6

Dipeptidyl Peptidase 4 Inhibitor

Boehringer Ingelheim

Approved

1 7

Questran

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 2

1 8

Rhgh

XXiamen Amoytop Biotech Co., Ltd.

Phase 3

1 9

Apraglutide

VVectivBio AG

Phase 3

2 10

Mytesi

NNapolitano Mariasanta

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Short Bowel Syndrome3 trials

Safety and Efficacy Study of Teduglutide in Subjects With Short Bowel Syndrome

Completed· Takeda logo

Takeda·Phase 3·NCT00081458·84 enrolled

Safety and Efficacy Study of Teduglutide in Subjects With Short Bowel Syndrome Who Completed Protocol CL0600-004 (NCT00081458)

Completed· Takeda logo

Takeda·Phase 3·NCT00172185·65 enrolled

Short Bowel Syndrome Research Study for Children Up To 17 Years of Age on Parenteral Nutrition

Completed· Takeda logo

Takeda·Phase 3·NCT02682381·59 enrolled

Safety and Efficacy1 trial

Safety and Efficacy of ALX-0600 in Subjects With Active Crohn's Disease

Completed· Takeda logo

Takeda·Phase 2·NCT00072839·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Teduglutide /kg. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Teduglutide /kg compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Teduglutide /kg. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Takeda company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Peptide[2]
Highest Phase: Phase 3[1]
Company: Takeda

Teduglutide /kg

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Short Bowel Syndrome3 trials

Safety and Efficacy1 trial

References

Drug Info

Quick Facts

Related News